Table 1 Comparison between various... | American Society of Hematology

Table 1

Comparison between various national and international guidelines in regard to splenectomy in the treatment of ITP

Guidelines	Year	Language	Publication site	Timing, indication, and restrictions for splenectomy
Guidelines	Year	Language	Publication site	Timing	Age, y	Stage	Indication for splenectomy
ASH	2011	English	Blood⁹	Deferred > 6 mo	NG	Second-line therapy after steroids; grade of recommendation IB
International consensus	2010	English	Blood⁸	Deferred > 6-12 mo	NG	One of the second-line therapies without preference
French	2009	French	www.has-sante.fr	Deferred > 12 mo	NG	Second-line after steroids, but TPO-mimetics or rituximab should be considered in some patients	Platelet count < 30 000/μL associated with bleeding
Norwegian	2011	Norwegian	www.legeforeningen.no/hematologi	Deferred > 6-12 mo	NG	Second-line after failure of steroid and/or rituximab
German	2010	German	Onkologie⁸⁸	Deferred > 12 mo	NG	Second-line after steroids but TPO-mimetics or rituximab should be considered in some patients	Platelet count < 30 000/μL associated with bleeding
British	2003	English	British Journal of Haematology⁸⁹	NG	65?	Second-line after failure of steroids
Swedish	2010	Swedish	www.sfhem.se	NG	NG	Second-line after failure of steroid in the absence of contraindication	Platelet count < 10 or < 30 000/μL and presence of bleeding or high steroid requirement

Guidelines	Year	Language	Publication site	Timing, indication, and restrictions for splenectomy
Guidelines	Year	Language	Publication site	Timing	Age, y	Stage	Indication for splenectomy
ASH	2011	English	Blood⁹	Deferred > 6 mo	NG	Second-line therapy after steroids; grade of recommendation IB
International consensus	2010	English	Blood⁸	Deferred > 6-12 mo	NG	One of the second-line therapies without preference
French	2009	French	www.has-sante.fr	Deferred > 12 mo	NG	Second-line after steroids, but TPO-mimetics or rituximab should be considered in some patients	Platelet count < 30 000/μL associated with bleeding
Norwegian	2011	Norwegian	www.legeforeningen.no/hematologi	Deferred > 6-12 mo	NG	Second-line after failure of steroid and/or rituximab
German	2010	German	Onkologie⁸⁸	Deferred > 12 mo	NG	Second-line after steroids but TPO-mimetics or rituximab should be considered in some patients	Platelet count < 30 000/μL associated with bleeding
British	2003	English	British Journal of Haematology⁸⁹	NG	65?	Second-line after failure of steroids
Swedish	2010	Swedish	www.sfhem.se	NG	NG	Second-line after failure of steroid in the absence of contraindication	Platelet count < 10 or < 30 000/μL and presence of bleeding or high steroid requirement

NG indicates not given.